GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Debt-to-Asset

Xbrane Biopharma AB (STU:7XB) Debt-to-Asset : 0.26 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Debt-to-Asset?

Xbrane Biopharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €8.52 Mil. Xbrane Biopharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €11.87 Mil. Xbrane Biopharma AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €79.41 Mil. Xbrane Biopharma AB's debt to asset for the quarter that ended in Mar. 2024 was 0.26.


Xbrane Biopharma AB Debt-to-Asset Historical Data

The historical data trend for Xbrane Biopharma AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Debt-to-Asset Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.01 0.06 0.06 0.35

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.25 0.27 0.35 0.26

Competitive Comparison of Xbrane Biopharma AB's Debt-to-Asset

For the Biotechnology subindustry, Xbrane Biopharma AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Debt-to-Asset falls into.



Xbrane Biopharma AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Xbrane Biopharma AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.783 + 13.911) / 58.422
=0.35

Xbrane Biopharma AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xbrane Biopharma AB  (STU:7XB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Xbrane Biopharma AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (STU:7XB) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines